Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03939481 · ClinicalTrials.gov registry record

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

A clinical trial of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by SWOG Cancer Research Network.

Active
Registry status
1,336
Enrollment target
20
Study locations

NCT03939481 is a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8 that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 1,336 participants, above the 289-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (362% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03939481, a study of Anatomic Stage III Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.

ACTIVE NOT RECRUITING
Registry status
1,336 participants
Enrollment target
20
Study locations

Study Summary

This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.

Interventions

  • OTHER Questionnaire Administration
  • OTHER Functional Assessment
  • DRUG Chemotherapy

Study Locations (20)

California

  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • Kaiser Permanente Dublin - Dublin
  • Kaiser Permanente-Fremont - Fremont
  • Kaiser Permanente-Fresno - Fresno
  • Kaiser Permanente-Oakland - Oakland
  • Desert Regional Medical Center - Palm Springs
  • Kaiser Permanente-San Francisco - San Francisco
  • Kaiser Permanente-Santa Teresa-San Jose - San Jose
  • Kaiser Permanente San Leandro - San Leandro
  • Kaiser San Rafael-Gallinas - San Rafael
  • Kaiser Permanente Medical Center - Santa Clara - Santa Clara
  • Kaiser Permanente-Santa Rosa - Santa Rosa
  • Kaiser Permanente Medical Center-Vacaville - Vacaville
  • Kaiser Permanente-Vallejo - Vallejo
  • Kaiser Permanente-Walnut Creek - Walnut Creek

Delaware

  • Bayhealth Hospital Kent Campus - Dover
  • Bayhealth Hospital Sussex Campus - Milford

Florida

  • Florida Gynecologic Oncology - Fort Myers
  • Regional Cancer Center-Lee Memorial Health System - Fort Myers

Colorado

  • Rocky Mountain Regional VA Medical Center - Aurora

Trial Details

FieldValue
Enrollment Target 1,336 participants
Start Date 2019-05-14
Est. Completion 2026-02-28

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT03939481

The ClinicalTrials.gov registry entry for NCT03939481 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,336 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 289-participant average among 84 other Anatomic Stage III Breast Cancer AJCC v8 trials with a reported enrollment target (362% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.

NCT03939481 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Delaware, Florida.

Frequently Asked Questions

What is clinical trial NCT03939481 about?

NCT03939481 is a clinical study titled "Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer". This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk...

What is the current status of trial NCT03939481?

This trial is currently active not recruiting. The enrollment target is 1,336 participants. The study started on 2019-05-14. Estimated completion is 2026-02-28.

What conditions does trial NCT03939481 study?

This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8.

What interventions are being tested in trial NCT03939481?

The interventions under investigation include: Questionnaire Administration (OTHER), Functional Assessment (OTHER), Chemotherapy (DRUG).

Who is sponsoring clinical trial NCT03939481?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03939481 being conducted?

This trial has 20 study locations across California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anatomic Stage III Breast Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.